Unlike in the rest of the country, where intestinal ultrasound rarely is used in the clinic, in New York City, gastroenterologists at Mount Sinai Hospital have made IUS findings the “the fifth vital sign” for inflammatory bowel disease patient care, particularly to monitor disease. Now, new research from the institution and other centers is showing that the tool can identify patients with endoscopic recurrence and possibly predict disease outcomes and treatment response.
Trending
- Colorectal cancer screening: An update to the American Cancer Society guideline, 2026 (American Cancer Society Journals)
- ‘Expanding the Funnel’: How Alternate Screening Methods Could Boost ASC GI Volumes (ASC News)
- Short-term profits or long-term health? ACP sounds warning on private equity in health care (Medical Economics)
- EoE Treatments Abound—If It’s Diagnosed Accurately (GI & Endoscopy News)
- Endoscopic drug depots for chronic GI Disease: A conversation with Edulis Therapeutics (GI & Hepatology News)
- Artificial intelligence-assisted endoscopists improve the detection rate of high-risk gastric lesions: A propensity score-matched retrospective study (World Journal of Gastroenterology)
- 5 GI power players (Becker’s GI & Endoscopy)
- Unio Health Partners and Thesis Care Announce Partnership to Scale AI-Powered Clinical Teams Across Specialty Care (Business Wire)
